BR112019005700A2 - uso de vírus oncolíticos otimizados e composição - Google Patents
uso de vírus oncolíticos otimizados e composição Download PDFInfo
- Publication number
- BR112019005700A2 BR112019005700A2 BR112019005700-5A BR112019005700A BR112019005700A2 BR 112019005700 A2 BR112019005700 A2 BR 112019005700A2 BR 112019005700 A BR112019005700 A BR 112019005700A BR 112019005700 A2 BR112019005700 A2 BR 112019005700A2
- Authority
- BR
- Brazil
- Prior art keywords
- virus
- oncolytic
- cells
- cell
- viruses
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32351—Methods of production or purification of viral material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400310P | 2016-09-27 | 2016-09-27 | |
| US62/400,310 | 2016-09-27 | ||
| US201662426724P | 2016-11-28 | 2016-11-28 | |
| US62/426,724 | 2016-11-28 | ||
| PCT/US2017/053659 WO2018064134A1 (en) | 2016-09-27 | 2017-09-27 | Optimized oncolytic viruses and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019005700A2 true BR112019005700A2 (pt) | 2021-07-27 |
Family
ID=60245169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019005700-5A BR112019005700A2 (pt) | 2016-09-27 | 2017-09-27 | uso de vírus oncolíticos otimizados e composição |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11253558B2 (https=) |
| EP (3) | EP3518947B1 (https=) |
| JP (3) | JP7138946B2 (https=) |
| CN (2) | CN117085047A (https=) |
| AU (1) | AU2017335673B2 (https=) |
| BR (1) | BR112019005700A2 (https=) |
| CA (1) | CA3037573A1 (https=) |
| MX (3) | MX2019003546A (https=) |
| WO (1) | WO2018064134A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7138946B2 (ja) * | 2016-09-27 | 2022-09-20 | セイター セラピューティクス エルエルシー | 最適化された腫瘍溶解性ウイルスおよびその使用 |
| CN108635380A (zh) * | 2018-04-13 | 2018-10-12 | 北京唯源立康生物科技有限公司 | 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用 |
| CN110387353B (zh) * | 2018-04-16 | 2023-07-18 | 厦门大学 | 一种用于治疗肿瘤的柯萨奇b组病毒 |
| CA3138657A1 (en) * | 2019-05-09 | 2020-11-12 | Sator Therapeutics LLC | Delivery of oncolytic viruses using dendritic cells |
| CN111494433A (zh) * | 2020-04-26 | 2020-08-07 | 吴建国 | 一种新型溶瘤病毒在制备治疗结直肠癌药物的用途 |
| CN116507721A (zh) * | 2020-08-14 | 2023-07-28 | 上海行深生物科技有限公司 | 构建溶瘤病毒的方法 |
| WO2023051607A1 (zh) * | 2021-09-29 | 2023-04-06 | 上海行深生物科技有限公司 | 病毒培养方法 |
| WO2024088585A1 (en) * | 2022-10-27 | 2024-05-02 | Technische Universität Berlin | Method for generation of tumor-adapted oncolytic viruses |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| JP5748656B2 (ja) * | 2008-05-22 | 2015-07-15 | ジェ イル ファーマシューティカル カンパニー リミテッド | 過剰増殖細胞の腫瘍抑制因子に基づいた腫瘍崩壊ウイルスに対する感受性を判定する方法 |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| AU2012204467B2 (en) | 2011-01-04 | 2016-08-18 | Sillajen, Inc. | Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus |
| US20140350087A9 (en) * | 2012-03-22 | 2014-11-27 | Halozyme, Inc. | Oncovector Nucleic Acid Molecules and Methods of Use |
| RU2519763C9 (ru) * | 2012-11-26 | 2015-04-27 | Ольга Вячеславовна Матвеева | Метод иммунотерапии онкологических заболеваний и фармацевтические композиции на основе онколитического вируса сендай |
| WO2014138314A1 (en) | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Oncolytic virus |
| HRP20200439T1 (hr) * | 2015-04-30 | 2020-06-12 | Psioxus Therapeutics Limited | Onkolitički adenovirus koji kodira protein b7 |
| JP7138946B2 (ja) | 2016-09-27 | 2022-09-20 | セイター セラピューティクス エルエルシー | 最適化された腫瘍溶解性ウイルスおよびその使用 |
-
2017
- 2017-09-27 JP JP2019538097A patent/JP7138946B2/ja active Active
- 2017-09-27 BR BR112019005700-5A patent/BR112019005700A2/pt not_active Application Discontinuation
- 2017-09-27 CN CN202310850191.XA patent/CN117085047A/zh active Pending
- 2017-09-27 MX MX2019003546A patent/MX2019003546A/es unknown
- 2017-09-27 EP EP17794108.5A patent/EP3518947B1/en active Active
- 2017-09-27 CA CA3037573A patent/CA3037573A1/en active Pending
- 2017-09-27 CN CN201780072002.3A patent/CN109982708B/zh active Active
- 2017-09-27 EP EP22151215.5A patent/EP4023233B1/en active Active
- 2017-09-27 WO PCT/US2017/053659 patent/WO2018064134A1/en not_active Ceased
- 2017-09-27 US US15/716,974 patent/US11253558B2/en active Active
- 2017-09-27 EP EP22151209.8A patent/EP4019029A1/en not_active Withdrawn
- 2017-09-27 AU AU2017335673A patent/AU2017335673B2/en active Active
-
2019
- 2019-03-27 MX MX2023011105A patent/MX2023011105A/es unknown
- 2019-03-27 MX MX2024004156A patent/MX2024004156A/es unknown
-
2021
- 2021-12-06 US US17/543,333 patent/US12521424B2/en active Active
- 2021-12-06 US US17/543,206 patent/US12357664B2/en active Active
-
2022
- 2022-08-31 JP JP2022137786A patent/JP7462345B2/ja active Active
-
2024
- 2024-03-18 JP JP2024042134A patent/JP2024069529A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117085047A (zh) | 2023-11-21 |
| JP7462345B2 (ja) | 2024-04-05 |
| CN109982708A (zh) | 2019-07-05 |
| EP4023233B1 (en) | 2026-01-07 |
| JP2022164823A (ja) | 2022-10-27 |
| JP7138946B2 (ja) | 2022-09-20 |
| EP4019029A1 (en) | 2022-06-29 |
| EP3518947C0 (en) | 2023-07-05 |
| US11253558B2 (en) | 2022-02-22 |
| AU2017335673A1 (en) | 2019-04-11 |
| US20220088097A1 (en) | 2022-03-24 |
| US12521424B2 (en) | 2026-01-13 |
| EP4023233C0 (en) | 2026-01-07 |
| MX2019003546A (es) | 2019-09-19 |
| JP2024069529A (ja) | 2024-05-21 |
| JP2019533015A (ja) | 2019-11-14 |
| EP3518947B1 (en) | 2023-07-05 |
| US20220088098A1 (en) | 2022-03-24 |
| WO2018064134A1 (en) | 2018-04-05 |
| US20180085411A1 (en) | 2018-03-29 |
| EP3518947A1 (en) | 2019-08-07 |
| AU2017335673B2 (en) | 2024-11-14 |
| CA3037573A1 (en) | 2018-04-05 |
| MX2023011105A (es) | 2023-10-02 |
| US12357664B2 (en) | 2025-07-15 |
| EP4023233A3 (en) | 2022-09-21 |
| EP4023233A2 (en) | 2022-07-06 |
| MX2024004156A (es) | 2024-04-23 |
| CN109982708B (zh) | 2023-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12521424B2 (en) | Optimized oncolytic viruses and uses thereof | |
| US20250084384A1 (en) | Chimeric poxvirus compositions and uses thereof | |
| Lorence et al. | Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus | |
| HUP0302278A2 (hu) | Neoplazmák kezelése vírusokkal | |
| Liu et al. | RETRACTED ARTICLE: Optimization of oncolytic effect of Newcastle disease virus Clone30 by selecting sensitive tumor host and constructing more oncolytic viruses | |
| Lech et al. | Use of attenuated paramyxoviruses for cancer therapy | |
| KR20060103890A (ko) | 세네카 밸리 바이러스에 기초한 조성물 및 질병의 치료방법 | |
| US10435672B2 (en) | Genetically stable oncolytic RNA virus, method of manufacturing and use thereof | |
| CN119709651A (zh) | 溶瘤病毒及其应用 | |
| WO2019015601A1 (zh) | 一种用于治疗肿瘤的病毒 | |
| WO2019201192A1 (zh) | 一种用于治疗肿瘤的柯萨奇b组病毒 | |
| CN109568350B (zh) | 一种用于治疗肿瘤的柯萨奇病毒 | |
| US20050031594A1 (en) | Pharmaceutical composition for treatment of cancers | |
| WO2020233102A1 (zh) | 一种治疗肿瘤或癌症的药物组合物和其应用 | |
| WO2019037642A1 (zh) | 一种用于治疗肿瘤的埃可病毒 | |
| US20240245739A1 (en) | Oncolytic virus based cancer therapy | |
| BR112019002646B1 (pt) | Composições de poxvírus quimérico e usos das mesmas | |
| WO2019204888A1 (pt) | Kit farmacêutico e seus usos | |
| HK1175495A1 (en) | New clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |